Sientra Inc (NASDAQ:SIEN) – Investment analysts at William Blair dropped their Q1 2019 earnings per share (EPS) estimates for shares of Sientra in a research report issued to clients and investors on Wednesday, March 13th. William Blair analyst M. Kaczor now expects that the medical instruments supplier will post earnings per share of ($0.67) for the quarter, down from their previous estimate of ($0.58). William Blair currently has a “Market Perform” rating on the stock. William Blair also issued estimates for Sientra’s Q2 2019 earnings at ($0.65) EPS, Q3 2019 earnings at ($0.62) EPS, Q4 2019 earnings at ($0.57) EPS, FY2019 earnings at ($2.50) EPS, Q1 2020 earnings at ($0.51) EPS, Q2 2020 earnings at ($0.54) EPS, Q3 2020 earnings at ($0.53) EPS, Q4 2020 earnings at ($0.60) EPS and FY2020 earnings at ($2.18) EPS.

Sientra (NASDAQ:SIEN) last posted its quarterly earnings results on Tuesday, March 12th. The medical instruments supplier reported ($0.86) EPS for the quarter, missing the consensus estimate of ($0.67) by ($0.19). The firm had revenue of $19.02 million for the quarter, compared to analyst estimates of $18.87 million. Sientra had a negative return on equity of 123.50% and a negative net margin of 121.28%.

Several other analysts also recently weighed in on SIEN. Zacks Investment Research upgraded shares of Sientra from a “sell” rating to a “hold” rating in a research report on Friday, November 16th. BidaskClub downgraded shares of Sientra from a “sell” rating to a “strong sell” rating in a research report on Tuesday, December 18th. Maxim Group upgraded shares of Sientra from a “hold” rating to a “buy” rating in a research report on Wednesday, December 19th. ValuEngine downgraded shares of Sientra from a “strong-buy” rating to a “buy” rating in a research report on Thursday, January 24th. Finally, Leerink Swann reduced their price objective on shares of Sientra from $22.00 to $18.00 in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and eight have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $19.50.

Shares of NASDAQ:SIEN opened at $8.34 on Friday. The company has a market cap of $325.46 million, a PE ratio of -2.57 and a beta of -0.04. The company has a quick ratio of 2.34, a current ratio of 2.77 and a debt-to-equity ratio of 0.36. Sientra has a twelve month low of $7.74 and a twelve month high of $26.79.

A number of hedge funds have recently added to or reduced their stakes in SIEN. Bank of America Corp DE raised its position in Sientra by 16.2% in the 2nd quarter. Bank of America Corp DE now owns 26,638 shares of the medical instruments supplier’s stock valued at $519,000 after purchasing an additional 3,718 shares during the last quarter. Bank of New York Mellon Corp raised its position in Sientra by 170.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 218,367 shares of the medical instruments supplier’s stock worth $4,261,000 after buying an additional 137,531 shares during the last quarter. Northern Trust Corp raised its position in Sientra by 74.2% during the 2nd quarter. Northern Trust Corp now owns 270,559 shares of the medical instruments supplier’s stock worth $5,278,000 after buying an additional 115,283 shares during the last quarter. Russell Investments Group Ltd. purchased a new position in Sientra during the 3rd quarter worth $1,186,000. Finally, JPMorgan Chase & Co. raised its position in Sientra by 6.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 163,888 shares of the medical instruments supplier’s stock worth $3,913,000 after buying an additional 9,245 shares during the last quarter. Hedge funds and other institutional investors own 92.79% of the company’s stock.

About Sientra

Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.

See Also: What are earnings reports?

Earnings History and Estimates for Sientra (NASDAQ:SIEN)

Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.